Overall verdict
Sell
3.2/10
1-year performance
-50.38%
Score breakdown
Down 50.4% over 1 year, 30% of the 52-week range.
Strongest: Growth 4.6/10. Weakest: Profitability 0.0/10.
16 analysts, target +0.1% vs the price.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
It also provides personalized health and wellness products ; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name ; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services.
Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Andrew Dudum
Founded
2017
Employees
2 442
Revenue / employee
961 358 USD
Next earnings
November 2, 2026 (estimated)
Institutional holders
- BlackRock, Inc.12.69%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.67%
- VANGUARD CAPITAL MANAGEMENT LLC4.22%
- STATE STREET CORP3.60%
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM3.54%
- MORGAN STANLEY3.16%
- Divisadero Street Capital Management, LP2.66%
- GEODE CAPITAL MANAGEMENT, LLC2.51%
- GOLDMAN SACHS GROUP INC2.29%
- Other institutions33.01%
- Rest of the register27.66%
509 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
65.30 USD
52-week low
13.74 USD
1-year performance
-50.38%
Declining
Year-to-date performance
-13.97%
Declining
Drawdown
-55.16%
Major drawdown
Position in the 52-week range
30% of range
Gross margin 54.2%, the company loses 5.5% of its revenue, ROIC -8.2%, ROE -32.0%.
Net margin
-5.51%
Negative
Sector 3.25%|S&P 12.97%
Gross margin
54.19%
Exceptional
Return on equity (ROE)
-32.03%
Negative
Sector 7.23%|S&P 16.52%
Return on invested capital (ROIC)
-8.20%
Negative
Free cash flow margin (FCF)
2.51%
Low
Margin stability
31.1 pts
Very uneven
Revenue to net income
Growth
4.6/10Revenue up 38.2% over 1 year, 73.6% a year over 5.
Revenue (trailing 12 months)
2.6Md USD
Revenue growth (1y)
38.25%
Hyper-growth
Revenue growth (3y)
345.54%
Hyper-growth
EPS growth (1y)
-320.75%
Declining
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
1.3/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 28.9x|S&P 23.0x
Forward P/E
69.9x
Very expensive
EV / EBITDA
—
N/A (loss)
Sector 12.6x|S&P 14.5x
PEG
—
Sector 0.75|S&P 0.86
P/E vs its own 5-year history
among the 41% lowest valuations
In line with its history
Market cap
6.6Md USD
Financial strength
1.5/10Cash covers 54.4% of the debt, net debt/EBITDA 3.1x.
Net debt / EBITDA
3.1x
Stretched
Gearing (net debt / equity)
217.60%
Stretched
Cash
841M USD
Cash / market cap
12.70%
Solid
Cash / total debt
54.39%
Solid
Net debt
705M USD
Equity
324M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 29.28 USD
- MM2028.59
- MM5029.72
- MM20027.81
- RSI 1450.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.35%
200-day average slope, 3 months
-15.90%
50-day average slope, 1 month
-7.63%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.75 % per day
Volatility change
-35.49%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.56 (11) | 0.35 (7) | 3 207 (15) | 294 (13) | -141 (8) |
| 2027 | 0.42 (11) | 0.82 (8) | 4 002 (15) | 401 (12) | 75 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 22, 2026.
Same sub-industry: 77 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CI | 6.9 | 7.0 | 70.9Md USD | 11.1x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 12.9 % | -8.0 % | ||
| 2 | LH | 6.7 | 5.9 | 24.7Md USD | 25.1x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.7 % | 10.4 % | ||
| 3 | CVS | 6.6 | 5.9 | 110Md USD | 22.7x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 10.7 % | 10.9 % | ||
| 4 | DVA | 6.6 | 6.5 | 11.7Md USD | 15.4x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.8 % | 32.3 % | ||
| 5 | BTSG | 6.4 | 4.9 | 11.0Md USD | 41.7x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.6 % | 102.1 % | ||
| 6 | DGX | 6.4 | 5.7 | 25.7Md USD | 24.7x | 9.2 % | 10.2 % | 7.9 % | 2.8x | 5.2 % | 26.9 % | ||
| 7 | FME | 5.3 | 6.7 | 12.0Md USD | 11.8x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 17.0 % | -10.0 % | ||
| 8 | GH | 4.7 | 2.6 | 23.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 189.0 % | ||
| 9 | HIMS | 3.2 | 1.6 | 6.6Md USD | Not meaningful (loss) | -5.5 % | 38.2 % | -8.2 % | 3.1x | 1.0 % | -50.4 % |
